These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 22776632

  • 1. One-year treatment continuation in patients prescribed risperidone long-acting injection in New Zealand: a retrospective study.
    Wheeler A, Vanderpyl J, Carswell C, Stojkovic M, Robinson E.
    Clin Schizophr Relat Psychoses; 2012 Jul; 6(2):61-8. PubMed ID: 22776632
    [Abstract] [Full Text] [Related]

  • 2. Explicit review of risperidone long-acting injection prescribing practice.
    Wheeler A, Vanderpyl J, Carswell C, Stojkovic M, Robinson E.
    J Clin Pharm Ther; 2011 Dec; 36(6):651-63. PubMed ID: 22023342
    [Abstract] [Full Text] [Related]

  • 3. Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries.
    Peuskens J, Olivares JM, Pecenak J, Tuma I, Bij de Weg H, Eriksson L, Resseler S, Akhras K, Jacobs A.
    Curr Med Res Opin; 2010 Mar; 26(3):501-9. PubMed ID: 20014981
    [Abstract] [Full Text] [Related]

  • 4. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J.
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [Abstract] [Full Text] [Related]

  • 5. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.
    Weiden PJ, Schooler NR, Weedon JC, Elmouchtari A, Sunakawa A, Goldfinger SM.
    J Clin Psychiatry; 2009 Oct; 70(10):1397-406. PubMed ID: 19906343
    [Abstract] [Full Text] [Related]

  • 6. Safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional, prospective study in schizophrenia and related disorders.
    Parellada E, Kouniakis F, Siurkute A, Schreiner A, Don L.
    Int Clin Psychopharmacol; 2010 May; 25(3):149-54. PubMed ID: 20305567
    [Abstract] [Full Text] [Related]

  • 7. The combined use of risperidone long-acting injection and clozapine in patients with schizophrenia non-adherent to clozapine: a case series.
    Se Hyun Kim, Dong Chung Jung, Yong Min Ahn, Yong Sik Kim.
    J Psychopharmacol; 2010 Jul; 24(7):981-6. PubMed ID: 19942641
    [Abstract] [Full Text] [Related]

  • 8. Risperidone long-acting injectable (Risperdal Consta®) for maintenance treatment in patients with bipolar disorder.
    Bobo WV, Shelton RC.
    Expert Rev Neurother; 2010 Nov; 10(11):1637-58. PubMed ID: 20977322
    [Abstract] [Full Text] [Related]

  • 9. Diffusion of a new drug: a comparative analysis of adoption, treatment complexity, and persistence of risperidone long-acting injectable therapy in the Netherlands.
    Pechlivanoglou P, Vehof J, van Agthoven M, de Jong-van den Berg LT, Postma MJ.
    Clin Ther; 2010 Jan; 32(1):108-18. PubMed ID: 20171417
    [Abstract] [Full Text] [Related]

  • 10. Predictors for starting depot administration of risperidone in chronic users of antipsychotics.
    Vehof J, Postma MJ, Bruggeman R, De Jong-Van Den Berg LT, Van Den Berg PB, Stolk RP, Burger H.
    J Clin Psychopharmacol; 2008 Dec; 28(6):625-30. PubMed ID: 19011430
    [Abstract] [Full Text] [Related]

  • 11. Treatment compliance in veterans administration schizophrenia spectrum patients treated with risperidone long-acting injectable.
    Duncan EJ, Woolson SL, Hamer RM.
    Int Clin Psychopharmacol; 2012 Sep; 27(5):283-90. PubMed ID: 22644368
    [Abstract] [Full Text] [Related]

  • 12. Experience with injectable long-acting risperidone in long-term therapy after an acute episode of schizophrenia: the SPHERE Study.
    De la Gándara J, San Molina L, Rubio G, Rodriguez-Morales A, Hidalgo Borrajo R, Burón JA.
    Expert Rev Neurother; 2009 Oct; 9(10):1463-74. PubMed ID: 19831836
    [Abstract] [Full Text] [Related]

  • 13. Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study.
    Barrio P, Batalla A, Castellví P, Hidalgo D, García M, Ortiz A, Grande I, Pons A, Parellada E.
    Int Clin Psychopharmacol; 2013 Jul; 28(4):164-70. PubMed ID: 23587986
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry.
    Olivares JM, Peuskens J, Pecenak J, Resseler S, Jacobs A, Akhras KS, e-STAR Study Group.
    Curr Med Res Opin; 2009 Sep; 25(9):2197-206. PubMed ID: 19604073
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Evaluation of health services use following the initiation of risperidone long-acting therapy among schizophrenia patients in the veterans health administration.
    Ren XS, Crivera C, Sikirica M, Dirani R, Qian S, Kazis LE.
    J Clin Pharm Ther; 2011 Jun; 36(3):383-9. PubMed ID: 21062329
    [Abstract] [Full Text] [Related]

  • 18. Risperidone long-acting injection (RLAI): the 12-week efficacy and tolerability in Thai patients with chronic schizophrenia.
    Arunpongpaisal S, Srisurapanont M, Kongsakon R, Kitiwattanagul K, Samanwongthai U.
    J Med Assoc Thai; 2010 Mar; 93(3):343-50. PubMed ID: 20420110
    [Abstract] [Full Text] [Related]

  • 19. Risperidone long-acting injection in Schizophrenia Spectrum Illnesses compared to first generation depot antipsychotics in an outpatient setting in Canada.
    Lammers L, Zehm B, Williams R.
    BMC Psychiatry; 2013 May 30; 13():155. PubMed ID: 23718192
    [Abstract] [Full Text] [Related]

  • 20. Prospective 6-month follow-up of patients prescribed risperidone long-acting injection: factors predicting favourable outcome.
    Taylor DM, Young C, Patel MX.
    Int J Neuropsychopharmacol; 2006 Dec 30; 9(6):685-94. PubMed ID: 16939663
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.